Name No. For Patients with Purpose
Mountaineer-03 23-25

Patients with HER2 positive colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable).

The main objective of the study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs.


Name No. For Patients with Purpose
FORTITUDE-101 23-17

Suitable for adult patients with previously untreated Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants with Fibroblast Growth Factor Receptor 2b (FGFR2b) over expression.

PaTcH Trial

Name No. For Patients with Purpose
PaTcH Trial 20-27

Metastatic refractory pancreatic cancer treated with trametinib and hydroxychloroquine

The goal of this study is to examine if Trametinib and Hydroxychloroquine will improve results for patients with advanced pancreatic cancer compared to standard chemotherapy.


Name No. For Patients with Purpose
KRYSTAL-10 21-06

Advanced Colorectal Cancer with KRAS G12C mutation with disease progression on or after standard first line therapy

To compare the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks

Name No. For Patients with Purpose
HERIZON-GEA-01 (ZWI-ZW25-301) Zymeworks 21-35

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic)

This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

DESTINY DS8201-A-U306  

Name No. For Patients with Purpose
DESTINY DS8201-A-U306   21-07

HER-2 positive metastatic and/or unresectable gastric or gasto-esophageal junction (GEJ) cancer

This study will evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd), a HER-2 targeting antinbody drug, compared with ramucirumab and paclitaxel (Ram + PTX) in participants with HER2-positive gastric or gastro-esophageal junction (GEJ) cancer who have progressed on or after a trastuzumab-containing regimen and have not received any additional systemic therapy.

Astellas 8951-CL-5201

Name No. For Patients with Purpose
Astellas 8951-CL-5201 CTRIAL-IE 18-44

Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM, and health-related quality of life (HRQoL).